SELLAS Life Sciences Group Inc.
SLS | NASDAQ
$11.76
+$0.39 (+3.43%)
Sep 22, 2026, 12:05 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Net Income | -26.86M | -30.88M | -37.34M | -41.3M | -20.7M | -16.76M |
Depreciation & Amortization | n/a | n/a | n/a | 457K | 5.69M | 282K |
Stock-Based Compensation | 1.96M | 1.56M | 1.39M | 1.73M | 1.01M | 578K |
Other Working Capital | -3.54M | -4.51M | 1.04M | 4.43M | -5.1M | 6.43M |
Other Non-Cash Items | 597K | 561K | 1.2M | 10.13M | -4.16M | -87K |
Deferred Income Tax | n/a | n/a | n/a | -457K | -239K | -23K |
Change in Working Capital | -4.08M | -6.65M | 3.35M | 5.64M | -7.62M | 5.59M |
Operating Cash Flow | -28.39M | -35.4M | -31.41M | -23.81M | -26.02M | -10.42M |
Capital Expenditures | n/a | n/a | -5.5M | -4.5M | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | -5.5M | -4.5M | n/a | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -527K | 594K | 90K | 85K | 3.07M | 8.84M |
Financial Cash Flow | 86.3M | 46.76M | 22.32M | 24.08M | 12.07M | 38.44M |
Net Cash Flow | 57.91M | 11.36M | -14.6M | -4.23M | -13.95M | 28.03M |
Free Cash Flow | -28.39M | -35.4M | -36.91M | -28.31M | -26.02M | -10.42M |
Adj. Free Cash Flow | -30.35M | -36.97M | -38.3M | -30.04M | -27.03M | -11M |
Maintenance CapEx | n/a | n/a | -5.5M | -4.5M | n/a | n/a |
Growth CapEx | n/a | n/a | n/a | n/a | n/a | n/a |
Owner Earnings | -28.39M | -35.4M | -36.91M | -28.31M | -26.02M | -10.42M |
Add to Watchlist
Select watchlists to add or remove SLS